Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Bispecific chimeric antigen receptor (CAR) targeting ROR1 and CD7 and application thereof

A chimeric antigen receptor and bispecific technology, which is applied to the bispecific chimeric antigen receptor and the application field of preparing antitumor drugs, can solve the problems of lack of CART cells, etc., to inhibit tumor growth and improve tumor target. The effect of improving tropism and expression level

Active Publication Date: 2022-02-18
冬青(天津)生物科技有限公司
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] It can be seen that there is still a lack of CART cells that can fully exert anti-tumor activity based on ROR1 targets, especially how to develop bispecific CART cells that include ROR1 targets, and how to select a second antigen that can produce synergistic benefits, so as to improve tumor therapy targeting. The above problems have become one of the research difficulties and hot spots in the field of CART. To solve the above technical problems, the present invention provides a novel bispecific CART, which lays a solid foundation for the further development of related antitumor drugs and therapies. technical basis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bispecific chimeric antigen receptor (CAR) targeting ROR1 and CD7 and application thereof
  • Bispecific chimeric antigen receptor (CAR) targeting ROR1 and CD7 and application thereof
  • Bispecific chimeric antigen receptor (CAR) targeting ROR1 and CD7 and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Embodiment 1: CART cell preparation

[0026] 1.1 Chimeric antigen receptor design

[0027] The bispecific chimeric antigen receptor provided in the present invention has the following structure: ROR1 scFv-X scFv-H-TM-C-CD3ζ where "-" is a connecting peptide or a peptide bond; H is a hinge region; TM is Transmembrane domain; C is a co-stimulatory signal molecule; CD3ζ is an intracellular signal transduction sequence; X scFv is selected from scFv targeting CD19, CD20, CD33, CD7 or CD3. The amino acid sequence and nucleotide sequence of each scFv were prepared and preserved by the inventors in earlier experiments.

[0028] 1.2 Viral vector transfection of T cells

[0029] In the present invention, multiple chimeric antigen receptor structures with bispecificity were constructed in order to verify the combined effects of ROR1 targets and other anti-tumor targets such as CD19, CD20, CD33, CD7 or CD3, for the convenience of distinction and follow-up Detection, respectively...

Embodiment 2

[0031] Example 2 In vitro tumor cell killing effect of CART cells

[0032] In order to verify the tumor killing effect of CART cells, K562 (chronic myeloid leukemia cell line) and Raji (lymphoma cell line) were selected as research objects in the present invention.

[0033] 2.1 Tumor cell culture

[0034] Remove and revive K562 cells and Raji cells from liquid nitrogen at 1 × 10 6 cells / mL inoculated in RPMI 1640 complete medium (containing 10% FBS), 37°C, 5% CO 2 Culture in a sterile cell culture incubator. Count and passage once every 48h, observe the state of the cells, when the cell survival rate reaches more than 80%, carry out subsequent experiments.

[0035] 2.2 CART cell co-culture

[0036] Harvest the CART cells and the above tumor cells separately, wash 3 times with sterile PBS, then mix the CART cells and tumor cells at a ratio of 2:1, and adjust the cell density to 1×10 6 cells / mL, inoculate in 96-well plate, carry out co-cultivation of CART cells and tumor ce...

Embodiment 3

[0041] Embodiment 3CART promotes cytokine release

[0042] The CART cells provided in the present invention are co-cultured with K562 cells, the specific method is the same as section 2.2. After co-cultivation for 48 hours, the cell supernatant was collected, and the contents of IFN-γ and TNF-α in the supernatant were detected using an ELISA kit (purchased from solarbio).

[0043] Such as image 3 As shown, after co-culture of CART cells and K562 cells, the expression level of IFN-γ can be greatly increased, and the bispecific CART targeting ROR1 and CD7 has the strongest ability to promote the secretion of IFN-γ, while the bispecific CART targeting ROR1 and CD7 has the strongest ability to promote IFN-γ secretion. Second, CARTs targeting ROR1 and CD19 bispecific CARTs and ROR1 and CD3 bispecific CARTs were relatively weak in inducing IFN-γ secretion.

[0044] Such as Figure 4 As shown, CART can also increase the expression level of TNF-α in the cell supernatant. Unlike IF...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a bispecific chimeric antigen receptor (CAR) targeting ROR1 and CD7 and application thereof, the bispecific chimeric antigen receptor (CAR) has the following structure: ROR1 scFv-CD7 scFv-H-TM-C-CD3 zeta, in which "-" is a connecting peptide or a peptide bond; H is a hinge area; TM is a transmembrane domain; C is a costimulatory signal molecule; and CD3zeta is an intracellular signal transduction sequence. The chimeric antigen receptor can inhibit tumor growth in vivo and in vitro, prolong the life cycle, promote cytokine secretion and play a synergistic anti-tumor role.

Description

Technical field: [0001] The invention belongs to the field of tumor immunotherapy, and specifically provides a bispecific chimeric antigen receptor (CAR) targeting ROR1 and CD7 and its application in the preparation of antitumor drugs. Background technique: [0002] At present, cancer has become one of the diseases with the highest fatality rate in the world. However, the existing methods such as surgical resection, radiotherapy and chemotherapy are effective in the treatment of early tumors, but it is difficult to treat patients in the middle and advanced stages, and it will also cause severe disease in patients. Adverse reactions affect the quality of life of patients and increase the burden on patients and their families. In recent years, with the development of tumor immunotherapy, Chimeric Antigen Receptor T Cells (CART) therapy has achieved great success in anticancer. This therapy was first proposed by Gross and colleagues in 1989, who fused the antigen-binding domai...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N15/62C12N5/10A61K39/00A61P35/00A61P35/02
CPCC07K16/2803C07K16/40C07K14/7051C12N5/0636A61K39/001162A61K39/001111A61P35/00A61P35/02C07K2317/622C07K2317/56C07K2317/565C07K2319/02C07K2319/03C07K2319/33C12N2510/00
Inventor 张克礼雷林均
Owner 冬青(天津)生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com